Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight loss only | Not covered |
| Type 2 diabetes and cardiovascular disease | Covered with PA |
Plan type: Commercial fully insured, individual and group. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
Coverage by indication
Independence Blue Cross discontinued coverage for GLP-1 and non-GLP-1 drugs prescribed solely for weight loss on January 1, 2025, for fully insured commercial members. The stated reason was a 45 percent year-over-year cost increase and a half-billion-dollar annual spend.
| Effective date | 2025-01-01 |
Source: Independence Blue Cross, Changes coming to weight loss drug coverage benefits, effective January 1, 2025. Official payer provider communications page (HTML, fetched directly). Verified June 12, 2026.
Independence Blue Cross continues to cover GLP-1s for FDA-approved conditions other than obesity, including type 2 diabetes and cardiovascular disease. Weight loss as a standalone indication is excluded as of January 1, 2025.
What the prior authorization needs:
- An FDA-approved medical indication, type 2 diabetes or established cardiovascular disease, must be documented
- Prior authorization is required
Source: Independence Blue Cross, Changes coming to weight loss drug coverage benefits, effective January 1, 2025. Official payer provider communications page (HTML, fetched directly). Verified June 12, 2026.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it.
- Start with the Independence Blue Cross prior-authorization letter template, which cites this plan's policy and the diagnosis codes a reviewer looks for. Pick the indication that matches your clinical picture.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- If your plan does not cover the indication you need, compare cash-pay options in the cost guide and the cheapest legitimate programs.
Frequently asked questions
Does Independence Blue Cross cover Wegovy or Zepbound?
No, not for weight loss. Independence Blue Cross stopped covering GLP-1 drugs prescribed solely for weight loss on January 1, 2025, for fully insured commercial members. It still covers GLP-1s with prior authorization when prescribed for type 2 diabetes or established cardiovascular disease. Policy verified June 2026 against the IBX provider communications page.
Does Independence Blue Cross have a step-therapy requirement for GLP-1s?
For the type 2 diabetes and cardiovascular indications, prior authorization is required but the published IBX policy does not specify a step-therapy drug the patient must fail first. The PA documentation must establish an FDA-approved medical indication (type 2 diabetes or cardiovascular disease) plus that the prescribing clinician has documented the diagnosis. There is no published step-therapy ladder requiring older diabetes drugs before a GLP-1 is approved, unlike some commercial plans.
Can I get a GLP-1 covered under Independence Blue Cross if I have type 2 diabetes?
Yes. Independence Blue Cross continued GLP-1 coverage for type 2 diabetes and cardiovascular disease when it removed the obesity-only weight-loss benefit effective January 1, 2025. You need a prior authorization from your prescribing clinician documenting the diabetes or cardiovascular diagnosis. The PA requirement applies to all covered indications.
Why did Independence Blue Cross stop covering GLP-1s for weight loss?
IBX cited a 45 percent year-over-year cost increase and approximately half a billion dollars in annual spend on anti-obesity medications as the reasons for the January 1, 2025 policy change. This is one of the largest commercial insurers to publicly exclude GLP-1s for the obesity indication while maintaining coverage for diabetes and cardiovascular uses.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
